Onconic Therapeutics Completes New Drug Application for Jakubo in Mexico for Erosive GERD
First Step Toward Entry into the Major Central and South American Market
Onconic Therapeutics has accelerated its expansion into the global market, recently completing both a successful Phase 3 clinical trial and a regulatory submission via a partner company in India. The company is now also taking a step closer to entering the large gastroesophageal reflux disease (GERD) market in Central and South America.
On June 9, Onconic Therapeutics announced that its independently developed new drug, Jakubo (active ingredient: Zastaprazan), has been submitted for New Drug Application (NDA) approval in Mexico for the treatment of erosive GERD.
Mexico is considered a high-potential market within the global erosive GERD segment due to its dietary habits, which include consumption of spicy foods and coffee, leading to an increasing prevalence of GERD. In particular, Mexico, along with Brazil, is regarded as a representative country in the Central and South American market, and entry into Mexico is seen as a strategic gateway for further expansion into the region.
This NDA submission in Mexico is being processed through the new abbreviated pathway, a fast-track review system introduced by Onconic Therapeutics' Mexican partner, Laboratorios Sanfer. This is expected to shorten the review period compared to the traditional process.
Laboratorios Sanfer, established in 1941, ranks first in Mexico in terms of sales and market share within the specialty pharmaceuticals sector. The company also holds a strong presence in the region, with subsidiaries in 19 countries across Central and South America, including Mexico. Through a technology transfer agreement signed in September 2024, Onconic Therapeutics has expanded into a total of 19 countries in the region—including Mexico, Argentina, Chile, and Colombia—and is currently preparing regulatory submissions for the remaining 18 countries following the initial application in Mexico.
Onconic Therapeutics expects that additional milestone payments associated with this regulatory submission and product launch will contribute to its revenue and operating profit for the year. As commercialization in Mexico draws closer, analysts anticipate that the company will begin to generate royalty income in earnest from the global GERD market—estimated at 40 trillion won—including China, India, and Central and South America.
Jakubo has continued its rapid growth in the domestic P-CAB market, driven by its excellent efficacy. Since its launch in Korea in October 2024, the drug recorded prescription sales of 21.2 billion won in the first quarter of this year. According to UBIST data, it achieved 8.5 billion won in April and 8.1 billion won in May, with expectations that second-quarter prescription sales will surpass 24 billion won, firmly establishing Jakubo as a blockbuster Korean-developed drug.
Additionally, in August last year, Onconic Therapeutics completed a regulatory application for erosive GERD in partnership with Livzon Pharmaceutical in China, and on May 29 entered Phase 3 clinical trials for a new indication in the Chinese market. After submitting a product license application in India earlier this month, the company has now filed for approval in Mexico, accelerating its pace of global expansion.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from Onconic Therapeutics stated, "Jakubo is the fastest-growing GERD treatment in Korea and is on track to reach the 100 billion won prescription milestone within just two years of launch. With development and commercialization outcomes accelerating in major overseas markets, we will continue striving to ensure that this original Korean new drug creates a global success story."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.